EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage



Armand Bensussan

Name of the laboratory

Immunology, Dermatologie & Oncology
Hôpital Saint Louis
Equerre Bazin
1 Avenue Claude Vellefaux
75475 Paris cedex 10, France
33 153 722 081

Members of the laboratory

Members: Immunology, Dermatologie and Oncology
Head of the Unit
Martine Bagot
Anne Marie-Cardine
Céleste Lebbé
Nicole Basset-Seguin
Vincent Descamps
Sébastien Jauliac
Caroline Ram-Wolff
Ph.D. Students
Adèle De Masson
Charlotte Hurabielle
Valérie Dessirier
Jocelyne André
Gabrielle Larcheron
Frédéric Guaddachi
Valérie Schiavon

Laboratory activity

Our laboratory is located at Saint Louis Hospital in Paris. We are working on the identification of new targets for the diagnosis and the therapy of skin diseases. Monoclonal antibodies are essential tools for determining the identification of these molecules. Dr. Armand Bensussan is the president of the French Association of Immunology, he is a member of the International HCDM (Human Cell Differentiation Molecules) Council.

Research activities

1. Physiopathology of Cutaneous T cell Lymphoma & Receptors of Innate Immunity

2. Oncogenesis of Melanoma

3. Epithelial pathophysiology, stem cells & tissue repair

Techniques available

  • Monoclonal antibody production in mice
  • Antibodies characterization
  • Multi-colour flow cytometry
  • Immunization with transfected cells

Publications (2016-present)

  • Bensussan A, Marie-Cardine A. (2018) CD160. In Encyclopedia of Signaling Molecules. Ed : S. Choi, Springer. Second Edition, p. 846-852.
  • Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, de Fontbrune FS, de Latour RP, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia. Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.
  • Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720.
  • Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly Ka So S, Hamidou Z, Bianovici S, Pouch J, Ducos B, Bonnet M, Bensussan A, Patatian A, Lati E, Wdzieczak-Bakala J, Choulot JC, Loing E, Hocquaux M. Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways. Br J Dermatol. 2017 Apr 12. doi: 10.1111/bjd.15577. [Epub ahead of print]
  • Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, Homyrda L, Bensussan A, Bagot M, Toubert A, Moins-Teisserenc H. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. Blood. 2017 Jul 31. pii: blood-2017-03-772996. doi: 10.1182/blood-2017-03-772996.
  • Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A. Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Sci Rep. 2017 Aug 3;7(1):7201. doi: 10.1038/s41598-017-07489-x.
  • Le Bouteiller P, Bensussan A. Up-and-down immunity of pregnancy in humans. F1000Res. 2017 Jul 25;6:1216. doi: 10.12688/f1000research.11690.1. eCollection 2017. Review.
  • Schmitt C, Marie-Cardine A, Bensussan A. Therapeutic antibodies to KIR3DL2 and other target antigens on cutaneous T-cell lymphomas. Front Immunol. 2017 Aug 30;8:1010. doi: 10.3389/fimmu.2017.01010. eCollection 2017. Review.
  • Battistella M, Leboeuf C, Ram-Wolff C, Hurabielle C, Bonnafous C, Sicard H, Bensussan A, Bagot M, Janin A. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 Oct 31. pii: blood-2017-06-792382. doi: 10.1182/blood-2017-06-792382.
  • Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R. Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair. Front Immunol. 2017 Oct 26;8:1413. doi: 10.3389/fimmu.2017.01413. eCollection 2017.
  • Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.
  • Brun C, Jean-Louis F, Oddos T, Bagot M, Bensussan A, Michel L. Phenotypic and functional changes in dermal primary fibroblasts isolated from intrinsically aged human skin. Exp Dermatol, 2016 Feb;25(2):113-9. doi: 10.1111/exd.12874. Epub 2016 Jan 11.
  • Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N. PARKIN Inactivation Links Parkinson's Disease to Melanoma. J Natl Cancer Inst, 2015 Dec 17;108(3). pii: djv340. doi: 10.1093/jnci/djv340. Print 2016 Mar.
  • Hurabielle C, Michel L, Ram-Wolff C, Battistella M, Jean-Louis F, Beylot-Barry M, d'Incan M, Bensussan A, Bagot M. Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. J Invest Dermatol, 2016 Jan;136(1):317-20. doi: 10.1038/JID.2015.360.
  • Lédée N, Petitbarat M, Chevrier L, Vitoux D, Vezmar K, Rahmati M, Dubanchet S, Gahéry H, Bensussan A, Chaouat G. The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After In Vitro Fertilization. Am J Reprod Immunol, 2016 Jan 18. doi: 10.1111/aji.12483. [Epub ahead of print
  • Joffre J, Hau E, Zeboudj L, Laurans L, Battistella M, Boufenzer A, de Masson A, Le Buanec H, Cochaud S, Bagot M, Bensussan A, Gibot S, Bouaziz JD, Ait-Oufella H. Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice. Exp Dermatol, 2016 Jan 19. doi: 10.1111/exd.12944. [Epub ahead of print]
  • Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, Tosi I, Morris SL, Moriarty B, Booken N, Felcht M, Quaglino P, Ponti R, Barberio E, Ram-Wolff C, Jäntti K, Ranki A, Bernengo MG, Klemke CD, Bensussan A, Michel L, Whittaker S, Bagot M, Tensen CP, Willemze R, Vermeer MH. Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: multicenter study of 59 cases. J Invest Dermatol, 2016 Feb 27. doi: 10.1016/j.jid.2016.01.038.
  • Laugier F, Delyon J, André J, Bensussan A, Dumaz N. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. Oncogene. 2016 Mar 14. doi: 10.1038/onc.2016.39. [Epub ahead of print]
  • Chasset F, De Masson A, Le Buanec H, Xhaard A, Sicre de Fontbrune F, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socie G, Bouaziz JD. APRIL levels are associated with disease activity in human chronic graft versus host disease. Haematologica. 2016 Mar 18. pii: haematol.2016.145409. [Epub ahead of print]
  • de Masson A, Bouaziz JD, Battistella M, Bagot M, Bensussan A. Immunopathology of psoriasis: from bench to bedside. Med Sci (Paris), 2016, 32(3):253-9. doi:10.1051/medsci/20163203009. Epub 2016 Mar 23.
  • Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma. Br J Dermatol, 2016 Apr 1. doi: 10.1111/bjd.14626.
  • Brun C, Maginiot F, Cras A, Wong H, Ly Ka So S, Larghero J, Bensussan A, Oddos T, Michel L. Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Exp Dermatol, 2016 May 19. doi: 10.1111/exd.13080.
  • De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A. Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. Oncoimmunology. 2016 Jan 13;5(5):e1127493. doi: 10.1080/2162402X.2015.1127493.
  • Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget. 2016 Jul 23. doi: 10.18632/oncotarget.10804.
  • Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget. 2016 Jul 16. doi: 10.18632/oncotarget.10634. [Epub ahead of print]
  • Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int J Mol Sci, 2016 Aug 30;17(9). pii: E1433. doi: 10.3390/ijms17091433. Review.
  • Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA. PLoS One. 2016 Oct 21;11(10):e0165031. doi: 10.1371/journal.pone.0165031
  • Brun C, Ly Ka So S, Maginiot F, Bensussan A, Michel L, Larghero J, Wong H, Oddos T, Cras A. Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Exp Dermatol, 2016 Nov;25(11):906-909. doi: 10.1111/exd.13080.
  • Lepelletier C, Bengoufa D, Lyes Z, de Masson A, Chasset F, Jachiet M, Michonneau D, Robin M, Peffault de Latour R, Sicre de Fontbrune F, Tandjaoui-Lambiotte Y, Bensussan A, Rybojad M, Tazi A, Bagot M, Socié G, Bergeron A, Bouaziz JD. Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatol, 2016 Nov 16. doi: 10.1001/jamadermatol.2016.3976. [Epub ahead of print]
  • Fabre J, Giustiniani J, Antonicelli F, Merrouche Y, Bensussan A. IL-17 and triple negative breast cancer. MOJ Immunology. 2016, 3(6) : 00110. doi :10.15406/moji.2016.03.00110
  • Lédée N, Prat-Ellenberg L, Chevrier L, Balet R, Simon C, Lenoble C, Irani EE, Bouret D, Cassuto G, Vitoux D, Vezmar K, Bensussan A, Chaouat G, Petitbarat M. Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study. J Reprod Immunol. 2016 Nov 24;119:23-30. doi: 10.1016/j.jri.2016.11.007
  • Delyon J, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.469. [Epub ahead of print]
  • Hurabielle C, Thonnart N, Ram-Wolff C, Sicard H, Bensussan A, Bagot M, Marie-Cardine A. Usefulness of KIR3DL2 to Diagnose, Follow-Up and Manage the Treatment of Sézary Syndrome Patients. Clin Cancer Res. 2017 Jan 24. pii: clincanres.3185.2016. doi: 10.1158/1078-0432.CCR-16-3185.

Patents (2013-present)

  • 2016 Invariant FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of γδ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Ex vivo generation of MHC II restricted CD4+ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
  • 2016 Immunotherapeutic uses of ex vivo generated FoxP3+ regulatory T cells, US patent, 5 august 2016
  • 2016 Monoclonal antibodies binding to the CD160 transmembrane isoform. EP 16306392.8, 25 october 2016
  • 2016 Combinations therapies for treatment of cancer. EP 16305540, 10 may 2016. Licensed to OREGA Biotech
  • 2015 Antibodies having specificity to myosin 18A and uses thereof. EP 15306108, 7 july 2015
  • 2015 Methods and pharmaceutical compositions for the treatment of BRAF inhibitor resistant melanomas. EP 15306865, 25 november 2015
  • 2013 KIR3DL2 is a biomarker and therapeutic target useful for respectively preventing and treating a subset of peripheral T-cell lymphomas. PCT/EP2013/061107, 29 may 2013
  • 2013 IL-17 antagonist antibodies. EP 13731758.2, 25 june, 2013 Licensed to OREGA Biotech

Biotechnology company

  • 2010/- OREGA-Biotech, 69000 Ecully, France
  • 2017/- Alderaan Biotechnology, 75005 Paris